SHAREHOLDER ALERT: Investigation of Reata Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) complied with federal securities laws. On August 10, 2020, Reata disclosed in its quarterly report for the second quarter of 2020 that the FDA "is not convinced that the MOXIe Part 2 results" of the Company's study assessing omaveloxolone for the treatment of Friedreich's ataxia is adequate to support a single study approval, thus "in preliminary comments for the meeting, the FDA stated that we will need to conduct a second pivotal trial." The price of Reata's stock fell following the announcement.
If you purchased shares of Reata and suffered a loss on that investment, you are encouraged to contact Marshall P. Dees, Esq. at [email protected] or Luke R. Kennedy, Esq. at [email protected], or by toll-free telephone at (888) 508-6832 to discuss your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.
News published on and distributed by:
